Comparative Pharmacology
Head-to-head clinical analysis: CU 7 versus SEASONIQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CU 7 versus SEASONIQUE.
CU-7 vs SEASONIQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The Cu-7 intrauterine device (IUD) releases copper ions, which inhibit sperm motility and viability, and alter the endometrial environment to prevent implantation.
Combination of ethinyl estradiol (estrogen) and levonorgestrel (progestin) that inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH); increases cervical mucus viscosity and alters endometrial receptivity.
50 mg orally once daily
One tablet daily orally: 84 days of ethinyl estradiol 0.02 mg / levonorgestrel 0.1 mg (active), followed by 7 days of ethinyl estradiol 0.01 mg.
None Documented
None Documented
Not applicable; intrauterine device with no systemic elimination half-life. Copper release is continuous with a rate of approximately 38 µg/day, declining over time.
Ethinyl estradiol: approximately 15.9 hours (range 9-28 hours); Levonorgestrel: approximately 24.4 hours (range 12-48 hours). Terminal elimination half-life accounts for steady-state attainment within 5-7 days.
Primarily fecal (80-90%) as unabsorbed copper; negligible renal excretion (<1%).
Renal: approximately 60% (as glucuronide and sulfate conjugates); Fecal: approximately 40% (as metabolites, with enterohepatic recycling).
Category C
Category C
Contraceptive
Contraceptive, Combination Hormonal